A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Phase of Trial: Phase II
Latest Information Update: 09 Apr 2018
At a glance
- Drugs NYX 2925 (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Sponsors Aptinyx
- 02 Apr 2018 Planned End Date changed from 30 Sep 2018 to 30 Oct 2018.
- 02 Apr 2018 Planned primary completion date changed from 30 Aug 2018 to 30 Oct 2018.
- 01 Aug 2017 According to an Aptinyx media release, first patient has been randomized.